Table 2.

Characteristics of autoimmune disorders (ADs) in 126 patients affected by thymic epithelial tumours (TET) vaccinated against SARS-CoV-2.

	Total number of patients affected	Currently active AD	Immunosuppressive treatment required	Steroids (at immunosuppressive dose)
Myasthenia gravis	23 (1)	15 (1)	18 (1)	7 (0)
Other AD	12 (5)	9 (4)	6 (3)	2 (0)
Myasthenia gravis + other AD	3 (0)	2 (0)	2 (0)	1 (0)
Total	38 (6)	26 (5)	26 (4)	10 (0)

Key: AD: Autoimmune Disorders; TET: Thymic Epithelial Tumour. In brackets, results for patients affected by thymic carcinoma are reported.